HCW Biologics to Raise $6.9 Million in Gross Proceeds From Direct Offering, Private Placement; Shares Extend Gains Premarket

MT Newswires Live11-19

HCW Biologics (HCWB) disclosed late Monday an agreement for a single institutional investor to purchase about 6.7 million shares in a registered direct offering priced above market under Nasdaq rules.

In a concurrent private placement, the company also agreed to issue unregistered warrants to purchase up to an aggregate of about 6.7 million shares.

The combined effective offering price for each share and accompanying warrants is $1.03. The warrants will have an exercise price of $1.03 per share, be exercisable immediately, and expire five years after the issuance date.

The gross proceeds from the registered direct offering and concurrent private placement are estimated to be about $6.9 million.

The offering will likely close on or about Nov. 20.

Shares of the company were up over 37% in premarket activity Tuesday after closing up 311% in regular trading on Monday.

Price: 1.7100, Change: +0.47, Percent Change: +37.90

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment